Novoic

What Novoic does

Novoic Ltd. is a London-based digital biotech company founded in 2019 that develops AI-enabled speech analysis software for the early detection of cognitive impairment and Alzheimer's neuropathology. The company's core technology consists of large audio and language models trained in-house on proprietary datasets, designed to identify subtle speech and linguistic biomarkers associated with preclinical and prodromal Alzheimer's disease. Its product suite includes Storyteller (a browser-based automated cognitive testing platform that runs on any smart device and completes assessment in approximately 10 minutes), Dashboard (an AI-assisted screening and patient funnel management tool with configurable triage from manual to fully automated), and Speech API (developer-facing access to the underlying speech processing, automated speech recognition, quality control, and biomarker models). Novoic has validated its algorithms through FDA-registered clinical trials (NCT04928976 and NCT04828122) in biomarker-confirmed prodromal and preclinical Alzheimer's populations, achieving what it describes as the first speech-based prediction of amyloid PET positivity with performance comparable to plasma tests.

The company generates revenue through subscription-based licensing of its AI-enabled cognitive screening software to healthcare and research institutions. Its go-to-market is enterprise-focused, targeting medical centers, hospitals, and clinical research organizations conducting Alzheimer's research and clinical trials, with deployment options via direct hosted access, SDK integration, or API. Novoic's stated customer base includes 50+ medical centers in the United States, and it maintains a strategic collaboration with the Alzheimer's Disease Neuroimaging Initiative (ADNI) to support early detection in underserved communities. The company emphasizes HIPAA and GDPR compliance, in-house quality management practices, and peer-reviewed scientific publications as credibility anchors for enterprise healthcare buyers.

The company operates as a privately held UK private limited company (Novoic Ltd.), with a small team (1-10 employees based on the most recent data) and is led by founding CEO Emil Fristed and co-founder/CTO Jack Weston. The disclosed funding footprint is modest, with approximately $2.6 million raised in a July 2020 seed round led by Anthemis Exponential Ventures alongside APEX Ventures, Entrepreneurs First, Plug and Play, and Stanford Angels and Entrepreneurs, suggesting an early-stage capital base relative to the scale of clinical claims and regulatory engagements it supports.

Name

Novoic

Legal name

Novoic Ltd.

Website

https://novoic.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Novoic Ltd. is a London-based digital biotech company that develops AI-enabled speech analysis software for early detection of cognitive impairment and Alzheimer's disease, serving healthcare institutions, medical centers, and clinical trial operators primarily in the United States.

Ownership category

akta.pro rank

Product category

Digital Health Cognitive Diagnostics Software

NAICS

Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Custom Computer Programming Services (541511)

SIC

Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD)

akta.pro secondary industries

SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

Keywords

• AI cognitive screening
• Speech biomarker analysis
• Alzheimer's detection software
• Digital neurology diagnostics
• Clinical trial patient screening

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Software Platform Licensing: AI-enabled cognitive screening software licensed to healthcare and research institutions for digital screening and monitoring at scale. Includes Storyteller platform, Dashboard, and Speech API modules.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Core offering

Novoic develops and licenses AI-enabled speech analysis software that detects subtle cognitive impairment and Alzheimer's neuropathology through speech biomarkers. Its platform is delivered to healthcare and research institutions via the Storyteller automated testing product, the Dashboard patient screening and analytics product, and the Speech API, supporting patient selection and monitoring for Alzheimer's clinical trials at 50+ US medical centers.

Product overview

Novoic offers a suite of three integrated AI-powered products for speech-based cognitive testing and early Alzheimer's disease detection. The core offering consists of Storyteller (automated online cognitive testing platform using AI speech biomarkers), Dashboard (AI-supported patient screening and management interface), and Speech API (developer access to underlying speech processing, ASR, quality control, and biomarker capabilities). These products work together as an end-to-end platform: Storyteller enables large-scale automated patient assessment, Dashboard provides clinical trial management and analytics, and Speech API allows custom integrations for organizations building their own applications.

Differentiator

Problem solved

Functional benefit

Brands

• Storyteller: Online automated testing platform leveraging state-of-the-art AI-based speech biomarkers to detect patients earlier with higher confidence.
• Dashboard
• Speech API

Products and services

• Storyteller

Quantifiable outcome

• Performance comparable to plasma tests for amyloid PET positivity prediction
• +3 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Partnerships

One partnership is on record.

• Alzheimer's Disease Neuroimaging Initiative (ADNI)coreStrategic or Co-development PartnerADNI is a major research initiative focused on Alzheimer's disease neuroimaging. Novoic collaborates with ADNI to support early detection in underserved communities across 50+ medical centers, combining speech-based cognitive testing with ADNI's biomarker research infrastructure to improve access to early Alzheimer's detection.

Scale indicators4 records

Direct peers

• Altoida: Altoida is a direct competitor offering AI-based digital cognitive assessment for early detection of Alzheimer's and other neurodegenerative diseases, using multimodal smartphone-based tests, similar in mission and end customers to Novoic.
• Linus Health: Linus Health (which acquired Winterlight Labs) provides AI-driven digital cognitive assessment including speech-based cognitive biomarkers, directly overlapping with Novoic's speech biomarker platform and clinical trial customer base.
• Cumulus Neuroscience: Cumulus Neuroscience offers a digital brain health platform combining speech, cognitive, and other biomarkers for clinical trials in CNS indications, competing for the same pharma trial patient-selection and monitoring use cases as Novoic.
• Cambridge Cognition: Cambridge Cognition provides digital cognitive testing (CANTAB) widely used in clinical trials and CNS research, overlapping with Novoic's enterprise research-customer segment and cognitive assessment category.
• Cogstate: Cogstate offers computerized cognitive testing and patient screening for clinical trials and healthcare, competing for the same clinical trial and cognitive assessment customers as Novoic.

Emerging players

• BrainCheck: BrainCheck provides a digital cognitive assessment platform for clinicians and researchers, with partial overlap to Novoic's cognitive screening offering, particularly in clinical and research settings.
• C₂N Diagnostics: C₂N Diagnostics offers the PrecivityAD blood test for amyloid detection, directly competing with Novoic's speech-based amyloid PET positivity prediction as a low-cost, scalable alternative to PET imaging.

Broad incumbents

• Roche / Genentech: Roche/Genentech is a large incumbent in Alzheimer's diagnostics and therapeutics (e.g., blood-based biomarkers, imaging), representing both a potential partner and broad competitive threat to Novoic's speech-based diagnostic positioning.
• Biogen: Biogen is a major Alzheimer's therapeutics developer (e.g., aducanumab, lecanemab co-marketer) and a likely sponsor/buyer of cognitive screening tools for clinical trial patient selection — both a key customer segment for Novoic and a broad incumbent.
• Eisai: Eisai co-developed lecanemab and runs large Alzheimer's clinical programs requiring cognitive screening and patient selection, making it both a potential enterprise customer and a broad incumbent shaping the screening-tools market.

Market position

Strengths4 records

Weaknesses4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novoic